Trial Profile
A Retrospective study of ceftolozane-tazobactam monotherapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2018
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2018 New trial record
- 19 Feb 2018 Results published in the Infection